× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|IO

Living evidence synthesis
about Immuno-Oncology drugs

Member of the meta|Evidence galaxy

Pathology  

Latest studies

Li, 2024

breast cancer - triple negative

camrelizumab plus SOC

KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 2019

breast cancer - triple negative

pembrolizumab alone

KEYNOTE-119 PD-L1 positive (CPS = 10 or more), 2019

breast cancer - triple negative

pembrolizumab alone

IMpassion-132, PD-L1 positive population, 2024

breast cancer - triple negative

atezolizumab plus SoC

Treatments

457
treatments 		  384
studies 		  1296
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons